Ophthotech $OPHT eyes Phase III clinical trial in 2021 for Best disease AAV genetherapy candidate being developed under rights from Penn uflorida httpow.lyW2yU30optJ5Â

Ophthotech ($OPHT) eyes Phase I/II clinical trial in 2021 for Best disease AAV #genetherapy candidate being developed under rights from @Penn, @uflorida: http://ow.ly/W2yU30optJ5 

17:55 EDT 12 Apr 2019 | Genetic Engineering News

Ophthotech ($OPHT) eyes Phase I/II clinical trial in 2021 for Best disease AAV #genetherapy candidate being developed under rights from @Penn, @uflorida: http://ow.ly/W2yU30optJ5 

More From BioPortfolio on "Ophthotech ($OPHT) eyes Phase I/II clinical trial in 2021 for Best disease AAV #genetherapy candidate being developed under rights from @Penn, @uflorida: http://ow.ly/W2yU30optJ5 "